Skip to content

A clinical trial to study the effect of magnesium sulphate in controlling blood pressure increase during laparoscopic cholecystectomy

Efficacy of low dose magnesium sulphate on attenuation of hemodynamic responses to tracheal intubation and carboperitoneum during laparoscopic cholecystectomy- a randomized, double-blind, placebo controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/09/007254
Enrollment
60
Registered
2016-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with cholecystitis undergoing laparoscopic holecystectomy and experiencing hemodynamic surges during laparoscopy

Interventions

Intervention1: Magnesium Sulphate: Injection magnesium sulphate I.P. 50% (w/v)added to 100 mL of normal saline and given as infusion over 10 minutes, before induction of anesthesia Control Interventio

Sponsors

Jaipur Golden Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA physical staus I and II patients 2. Aged 20-60 years 3. Both sexes 4. Presenting for elective laparoscopic cholecystectomy under general anesthesia.

Exclusion criteria

Exclusion criteria: 1. Patients who do not give informed consent. 2. ASA III and above patients. 3. Patients with history of neuromuscular disease, drug or alcohol abuse, coronary artery disease (CAD), cardiac arrhythmia, hypermagnesemia, neuromuscular disease, increased intraocular pressure, hiatal hernia, or gastroesophageal reflux. 4. Patients with anticipated difficult airway. 5. Patients taking calcium channel blockers. 6. Patients having known sensitivity to the study drug. 7. Pregnant women and lactating mothers 8. Patients in whom surgery could not be completed laparoscopically.

Design outcomes

Primary

MeasureTime frame
Attenuation of hemodynamic surges during intubation and those due to pneumoperitoneumTimepoint: immediately after intubation, 3 minutes after intubation, then throughout pneumoperitoneum

Secondary

MeasureTime frame
Reduced incidence of post-operative nause, vomiting and shiveringTimepoint: Immediate post-operative period to 120 minutes post-operatively

Countries

India

Contacts

Public ContactDr Ramesh Subedi

Jaipur Golden Hospital

swaranbhalla3@gmail.com91981168954

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026